Closing the stable door after the horse has bolted: should we be treating people with immune-tolerant chronic hepatitis b to prevent hepatocellular carcinoma?

HIGHLIGHTS

• who: Jessica Howell from the It is logical that the carcinogenic risk of HBV starts from the time of infection, is cumulative, and is driven by integration events associated with high-level viral replication, as well as progressive fibrotic liver damageEarly viral suppression is likely to minimize the risk of HCC by reducing integration and preventing cirrhosis. Treatment for all would also simplify clinical management algorithms, promoting public health interventions for control of CHB. In an era where effective NA are cheap and safe, there is a need to define the benefit of a "treat-all" approach . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.